Biotech Peptides
$43.00- Price / mg
- $8.60
- Document access
- Public link
Free USPS Priority over $200; lower-order rate not stated
Three public US 5 mg Sermorelin research listings compared on exact nominal size and current list price, with seller evidence language, availability state, shipping claim, and checked date attached.
Current answer. As of Jul 23, 2026, 2 confirmed in-stock listings run from $43.00 to $49.49, with a $46.25 median across the in-stock rows. All 3 seller pages remain visible below.
Free USPS Priority over $200; lower-order rate not stated
Free US shipping claimed
A list-price starting point, not a product-quality, safety, or seller recommendation.

List price, document access, and final landed cost answer different questions. This view keeps them separate instead of turning them into one seller score.
Free USPS Priority over $200; lower-order rate not stated
Open vendor evidence profile →COA, LC, and MS images. Access is public, but authenticity and custody are not established.
Inspect transparency record →This difference compares list prices only. It does not assign value to a report or include shipping.
Calculate landed cost →How to read it: The Biotech Peptides row is both the lowest confirmed in-stock list price and the lowest row with a public document route. Document visibility is not product verification.
Filter Sermorelin vendors by stock, price, and public documents →Rank rule. Price rank is availability-aware and stays fixed when you search or re-sort this view. Affiliate status never enters the calculation.
Compare two lowest in-stock rowsChecked July 28, 2026 at 4:47 PM UTC. Confirmed means the public source matched the published price and returned a reliable current availability signal. No row needs manual review. This does not verify vial contents or product quality.
Open source-check ledger| Price rank / supplier | 5 mg price | Price / mg | Public evidence | Shipping claim | Open listing |
|---|---|---|---|---|---|
01Biotech PeptidesLowest confirmed in-stock list priceIn stock | $43.00Source confirmed | $8.60 | COA, LC, and MS imagesAccess: Public link · Seller claim · Jul 23, 2026 | Free USPS Priority over $200; lower-order rate not stated | |
02Pepta LabsFree US shipping claimedIn stock | $49.49Source confirmed | $9.90 | COA on requestAccess: On request · Seller claim · Jul 23, 2026 | Free US shipping claimed | |
03Core PeptidesPrice shown; stock label absentStatus not stated | $48.00Source confirmed | $9.60 | COA tab shownAccess: Public link · Seller claim · Jul 23, 2026 | Free over $200; lower-order rate at checkout |
1 In-stock headline prices exclude unavailable listings, coupons, and checkout-only discounts.
2 A seller COA or report is labeled as a claim unless Peptide Local commissioned the sample and controlled custody.
How we read a certificate of analysis →How to verify the seller and access route →Start with how the document can be reached, then match it to this exact Sermorelin 5 mg row. Access is useful evidence, but it does not prove authenticity, custody, vial contents, sterility, or suitability.
The exact 5 mg page displayed an ordering control and seller-hosted analytical images. Peptide Local did not commission the testing or verify that the represented batch corresponds to shipped material.
The exact 5 mg listing was marked in stock and described independent HPLC purity and ESI-MS identity documentation available by request. Peptide Local did not obtain the vial.
The exact 5 mg page exposed a price, ordering control, and certificate-of-analysis tab. A distinct stock statement was not captured, so the row is availability-unconfirmed.
The free checker keeps compound identity, lot matching, dates, laboratory attribution, report verification, custody, purity, identity testing, instrument output, and quantity separate.
These canonical matchups open directly on the Sermorelin 5 mg board. Price, stock, document access, source freshness, and shipping stay separate.
Biotech Peptides is $6.49 lower before shipping.
Biotech Peptides is the only row marked in stock.
Pepta Labs is the only row marked in stock.
Pair selection prioritizes rows that are currently comparable, include the board low, or expose a meaningful document-access contrast. It is not a seller ranking.
The public list price moved from $44.99 in Peptide Local's 2026-07-17 snapshot to $49.49 after four matching source checks. That is a $4.50 increase, or 10.00%.
The listing was recorded as in stock at publication and displayed at price position 2 on the current exact-size board. Unavailable rows cannot set the current in-stock low. Price movement does not establish product identity, quality, safety, or market-wide inflation.
Open the complete Sermorelin price history →Open the full peptide price change record →FDA records show that Geref, a sermorelin acetate prescription product, was approved in 1997; FDA later documented withdrawal of its approvals after commercial discontinuation. Current research-vial listings are not that approved product or supply chain.
Read the FDA orphan-drug record ↗Price, chemical identity, clinical evidence, approved-product status, and local supply are different questions. This map shows which source answers each one and leaves unresolved fields visible.
Evidence routes checked through Jul 23, 2026This record resolves current seller-labelled sermorelin research listings. FDA records show that the Geref sermorelin acetate prescription product was approved and that its approvals were later withdrawn after commercial discontinuation. Current research vials are not that historical product and do not inherit its former application, label, evidence, manufacturing, or supply chain.
Read the FDA orphan-drug recordaccessdata.fda.gov↗The price board can compare current list price, nominal size, availability, shipping language, and seller document access. It cannot establish identity, quantity, purity, sterility, legality, or fitness for use.
Inspect every price and source row2 currently confirmed in stock↓Sermorelin is outside Peptide Local's current 13-program trial-count snapshot. That means no local count is published here, not that the count is zero. Search the live registry, then inspect the intervention, status, population, and posted results for each record.
Search Sermorelin on ClinicalTrials.govLive official registry route, not a cached result count↗The global index joins this identity to official product and seller or supply routes in 22 content languages. Only 0 countries currently have a separate compound-specific status finding in this dataset.
Open the complete worldwide mapIdentity, product, seller, and supply checks stay separate↗The routes below are still useful, but they connect the identity to general official records. Missing compound-specific evidence is not a legal or availability conclusion.
No compound-specific United States finding is attached to this snapshot. The exact guide connects Sermorelin to official product and seller or supply checks. That absence is not evidence of approval, prohibition, legality, availability, or seller authority.
No compound-specific Canada finding is attached to this snapshot. The exact guide connects Sermorelin to official product and seller or supply checks. That absence is not evidence of approval, prohibition, legality, availability, or seller authority.
No compound-specific France finding is attached to this snapshot. The exact guide connects Sermorelin to official product and seller or supply checks. That absence is not evidence of approval, prohibition, legality, availability, or seller authority.
No compound-specific México finding is attached to this snapshot. The exact guide connects Sermorelin to official product and seller or supply checks. That absence is not evidence of approval, prohibition, legality, availability, or seller authority.
No compound-specific Australia finding is attached to this snapshot. The exact guide connects Sermorelin to official product and seller or supply checks. That absence is not evidence of approval, prohibition, legality, availability, or seller authority.
It can show the visible list price, normalized unit cost, availability label, delivery claim, document language, destination market, and date checked.
A seller page or uploaded certificate does not replace independent sampling, chain-of-custody evidence, regulatory authorization, or professional judgment.
Current exact-size answers for price, document access, shipping, and source checks. No seller is converted into a product-quality or safety recommendation.
As of Jul 23, 2026, the lowest confirmed in-stock public list price in Peptide Local's exact-size US research-market sample is $43.00 from Biotech Peptides. Shipping, tax, coupons, subscriptions, bundles, and checkout-only fees are not included.
1 confirmed in-stock row link to a public seller document route: Biotech Peptides. The lowest of those rows is Biotech Peptides at $43.00. Public access does not authenticate a report, establish custody, or prove the contents of a supplied vial.
No. The board compares public single-unit list prices for the same 5 mg nominal size. The current lowest row states: Free USPS Priority over $200; lower-order rate not stated. Use the landed-cost calculator before treating the list-price order as the final order cost.
Confirm the exact identity and nominal size, current availability, landed cost, seller identity, destination-market rules, document route, lot or batch matching, analytical method, and source date. A seller-labelled research listing is not an approved medicine and public price or document access does not establish identity, purity, quantity, sterility, safety, legality, or fitness for human use.
Start by matching the exact Sermorelin identity and 5 mg listing to a current lot or batch identifier. Then check analysis date, named laboratory, report verification route, sample custody, separate purity and identity methods, instrument output, and any measured quantity result. Peptide Local's free ten-field checker can organize those questions, but document completeness does not prove authenticity or the contents of a supplied vial.
These pair guides compare research-market identity, exact board size, seller overlap, price footprint, and evidence access. They do not rank effects or recommend personal use.
These guides explain local verification and access routes. They do not relabel this US research-price board as local inventory or medical availability.